الفهرس 
Introduction&Aim of the workOnly 14 pages are availabe for public view
 |  | from | 216 |  |  |
| | | from | 216 | | |
Abstract
•Coronary artery disease is the leading cause of morbidity and mortality in the world. Central to the pathogenesis of CAD is the development of atherosclerotic lesions in coronary arteries. These lesions, if unstable or clinically significant, are frequently treated with PCI. The goal of therapy in patients with CAD is to alleviate symptoms of angina and reduce the risk of death or nonfatal MI.•Coronary revascularization is built on centuries of research. The three major milestones in the evolution of interventional cardiology were the development of the angioplasty balloon by Andreas Grüntzig 1977, the introduction of the coronary artery stent, and the development of DES.•Despite the benefits of DES, there is still a role for BMS in the management of patients with CAD. For patients whose risk of restenosis is relatively low (i.e., non-diabetic, large vessel <3 mm in diameter), and/or the risk of ST is relatively high (inability to comply with long-term DAPT), a BMS maybe more appropriate. •Ongoing problems, particularly with the need for late target TLR and very late ST, have prompted the development of a third generation of DES technology. The emerging third generation of DES, including A- biodegradable polymer, B-polymer free and C-fully biodegradable stents, aims to overcome the limitations of current stent technology. Despite significant recent interest in biodegradable scaffolds, clinical and trial experience is limited.•The stent technology which will dominate in the future will be that which optimizes patient outcomes and best meets the needs of the contemporary interventionalist in a cost effective manner. It must have excellent efficacy and safety, deliverability in broad range of clinical settings, minimal limitations on non-invasive imaging and future revascularization procedures, and limit the need for prolonged DAPT.